{"nctId":"NCT01808690","briefTitle":"EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes","startDateStruct":{"date":"2013-03"},"conditions":["Type 1 Diabetes"],"count":52,"armGroups":[{"label":"Metformin","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Metformin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Adolescents 12-21 years of age with type 1 diabetes (defined as having positive antibodies as well as insulin requirement)\n2. Willing to consent for participation in study\n3. Body Mass Index (BMI) \\>5% on growth charts\n\nExclusion Criteria:\n\n1. Current use of medications known to affect insulin sensitivity: oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, metformin or thiazolidinediones.\n2. Currently pregnant or breastfeeding women\n3. Use of a thiazolidinedione within 12 weeks\n4. Severe illness or Diabetic Ketoacidosis within 60 days\n5. Macroalbuminuria\n6. Hemoglobin A1c \\> 12%\n7. Weight \\> 136.4 kg or \\< 42 kg, BMI \\< 5%\n8. Creatinine \\> 1.2\n9. Hemoglobin \\< 9\n10. Major psychiatric or developmental disorder limiting informed consent\n11. Implanted metal devices\n12. Inability to tolerate ≥500mg twice a day of metformin","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Insulin Sensitivity","description":"Hypothesis 1: Metformin will improve insulin function in Type 1 Diabetes. Insulin function will be measured using a euglycemic-hyperinsulinemic clamp procedure at both baseline and after 3 months of treatment. A clamp measures insulin sensitivity. A higher number indicates a better outcome; a lower number indicates a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"3.2"},{"groupId":"OG001","value":"-2.4","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Change in ADP Time Constant","description":"Hypothesis 1b: Metformin will improve mitochondrial function in Type 1 Diabetes. 31Phosphorus magnetic resonance spectroscopy (MRS) was used before, during, and after 90 seconds of near-maximal isometric exercise of the calf muscle for post-exercise muscle mitochondrial function. ADP time constant is the time for conversion of ADP → ATP and is a measure of muscle mitochondrial health (energy metabolism).\n\nA faster recovery is a better outcome; a slower recovery is a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":null},{"groupId":"OG001","value":"-0.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Pulse Wave Velocity (PWV)","description":"Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via pulse wave velocity (PWV) by MRI. PWV is a measure of central arterial stiffness.\n\nA lower value indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.2"},{"groupId":"OG001","value":"4.1","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Change in Central Arterial Intimal Medial Thickness (cIMT)","description":"Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via central arterial intimal medial (cIMT) thickness by carotid ultrasound. cIMT is a measure used to diagnose the extent of carotid atherosclerotic vascular disease. The test measures the thickness of the inner two layers of the carotid artery-the intima and media.\n\nA lower result is a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.01"},{"groupId":"OG001","value":"0.00","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change in Mitral Valve E/A Ratio by Echocardiogram","description":"Hypothesis 2b: Metformin will improve cardiac function in Type 1 Diabetes by echocardiogram.\n\nMitral Valve E/A ratio is the ratio of early (E) to late (A) ventricular filling velocities.\n\nIdeal myocardial tissue relaxation is indicated by a ratio of \\>0.8 and \\<2.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"0.42"},{"groupId":"OG001","value":"1.72","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Change in Aortic Wall Sheer Stress (WSS)","description":"Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via Aortic Wall Sheer Stress (WSS) by MRI. WSS is a measure of central arterial stiffness.\n\nA lower value indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.4"},{"groupId":"OG001","value":"1.5","spread":"0.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Brachial Artery Distensibility","description":"Hypothesis 2a: Metformin will improve peripheral arterial stiffness in Type 1 Diabetes via Dynapulse.\n\nPeripheral arterial stiffness is measured by the distensibility of the arterial wall. Increased arterial stiffness results from reduced elasticity of the arterial wall.\n\nA higher result is a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"0.19"},{"groupId":"OG001","value":"0.16","spread":"0.20"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Gastrointestinal Side Effects"]}}}